Sign up USA
Proactive Investors - Run By Investors For Investors

Lannett Company gets FDA nod for generic flu drug

"We expect to launch the product in time for the coming flu season,” said Arthur Bedrosian, Lannett chief executive.
flu patient
Its the first product to clear FDA approval after pharmacokinetic by DarmanTest

Generic drug manufacturer Lannett Company Inc (NYSE: LCI) is looking forward to the next flu season after securing approval for a new product, comparable to the Symmetrel branded treatment.

The Food and Drug Administration (FDA) has signed off Lannett’s Amantadine Hydrochloride Capsules, described as being the ‘therapeutic equivalent’ of the reference standard drug which is produced by Sandoz Pharmaceuticals.

"While this approval comes too late to benefit fiscal 2017, which ends later this month, we expect to launch the product in time for the coming flu season,” said Arthur Bedrosian, Lannett chief executive.

He also highlighted that the approval was approved in 15 months, and it represents the first product to be approved following bio-equivalency study at the company’s pharmacokinetic subsidiary, DarmanTest Laboratories.  

Jamie_55a91591db06b.jpg


Register here to be notified of future LCI Company articles
View full LCI profile View Profile

Lannett Company Timeline

Newswire
February 10 2011

Related Articles

stem cell
June 12 2017
"With multiple value upside triggers ahead, including imminent maiden revenues from CellPlan, I very much look forward to the opportunities ahead" - CEO João Andrade
1-Operation.jpg
January 18 2017
Deltex’s overseas sales are booming but its previously dominant NHS revenues are dropping off
shutterstock_127456451.jpg
March 30 2017
PIFA Heparin PF/4 - a diagnostic test for allergic reactions to blood thinning agent Heparin - achieved an 85% jump in sales in 2016
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use